The BioWorld Insider Podcast
One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.
- Update frequency
- every 29 days
- Average duration
- 22 minutes
- Episodes
- 50
- Years Active
- 2021 - 2025
The biosimilars challenge to Humira revs up
Guests BioWorld Regulatory Editor Mari Serebrov and Tom Newcomer, Samsung Bioepis vice president and head of U.S. market access, discuss the launch of biosimilars that are taking on a blockbuster.
Preventing opioid overdoses with a smart patch
Brad Holden, CEO of Resilient Lifescience, explains how the device works for overdoses as well as other potential applications for this new technology.
Better times ahead for the biopharma sector? Could be, the new numbers say
Karen Carey, BioWorld’s managing editor and senior data analyst, and Tim Shannon, a general partner at Canaan, break down the numbers from first quarter of 2023.
Hosted on Acast. See acast.com/priva…
Radiopharmaceuticals: The next big disrupter?
BioWorld Staff Writer Tamra Sami talks about the science behind radiopharmaceuticals, the supply chain vulnerabilities, the regulatory landscape, the patient journey and therapies in the pipeline.
H…
Cambrian carves out a new niche as it works to keep people from getting sick
James Peyer, the CEO of Cambrian Biopharma Inc., talks about anti-aging therapies, a business model that fits the new field of geroscience.
Hosted on Acast. See acast.com/privacy for more informatio…
Rethinking obesity: Fitness may be more directly linked to health than weight
BioWorld Science Managing Editor Anette Breindl discusses her new analysis of multiple studies related to weight loss, metabolic health and fitness that in many ways go against mainstream theories …
Looking ahead to 2023: CEOs contemplate the new normal
Guests Karen Zaderej, CEO of Axogen Inc., Sean Bohen, CEO of Olema Oncology Inc., Rob Ross, the CEO of Surface Oncology Inc., and Rob Etherington, the CEO of Clene Nanomedicine Inc., speak about adap…
Psychedelic evolution: Mindset Pharma looks to change mental health treatment
James Lanthier, the CEO of Mindset Pharma Inc., talks about developing next-generation psychedelic medicines to treat neurological and psychiatric disorders.
Hosted on Acast. See acast.com/privacy f…
$1B+ biopharma deals keep values afloat, even amid muted volume
BioWorld Senior Analyst Karen Carey chats about the collision of a volatile economic climate and big biopharma deals.
Hosted on Acast. See acast.com/privacy for more information.
Extending the human lifespan
Extending the human lifespan, a BioWorld special report, examines the companies developing “Fountain of Youth” drugs. In this episode, the writers discuss this scientific holy grail.
Hosted on Acas…
New therapies vie to change the fatal course of amyotrophic lateral sclerosis
Executives from Amylyx Pharmaceuticals Inc. and Clene Inc., along with a key Penn State ALS expert, discuss what the future of medicine holds for patients.
Hosted on Acast. See acast.com/privacy for…
Biopharma’s correction? 2022 1Q investments are both up and down
BioWorld Senior Analyst Karen Carey explores the newest data and where it is leading.
Hosted on Acast. See acast.com/privacy for more information.
Who advises the CDC on big COVID decisions?
Infection control expert William Schaffner of the Vanderbilt University School of Medicine joins to discuss the CDC’s Advisory Committee on Immunization Practices and how COVID-19 put the committee’s…
Long COVID: Potentially the next public health crisis
Senior Science Editor Anette Breindl goes in depth about how long COVID-19 emerged and is being defined.
Hosted on Acast. See acast.com/privacy for more information.
What happens when your inventor is an artificial intelligence?
Guests Ryan Abbott, a professor of law and medicine, as well as the leader of the Artificial Inventor Project, and Jim Belfiore, senior vice president of innovation at Clarivate plc, have a discussio…
Another record year for biopharma financings bodes well for 2022
A conversation with Kleanthis Xanthopoulos, a co-founder and executive chairman of Shoreline Biosciences, and Joe Hernandez, CEO and executive chairman of Blue Water Vaccines, who have founded or led…
Aduhelm’s hard lessons and what it means for other Alzheimer’s drugs
Insights into the controversial drug come from guests Michael Agadjanyan, president of Nuravax Inc., which is developing antibodies for preventing Alzheimer’s and Parkinson’s diseases, along with Rob…
Supply Chain Geeky: Managing through the challenges of COVID-19 with an eye to what’s at stake
Paul Testa, executive vice president for operations and supply chain at Tokyo-based Kyowa Kirin, on the dramatic importance of continuity, reliability of supply, business process and automation.
Ho…
Regulatory Gemish: COVID-19’s big impacts on the FDA and beyond
Peter Pitts, president of the Center for Medicine in the Public Interest, on how government regulation seems like a slow but in actuality moves more quickly than understood.
Hosted on Acast. See aca…
Reality check: How did industry develop COVID-19 vaccines and drugs so fast?
BioWorld Regulatory Editor Mari Serebrov puts the pandemic and the science into perspective.
Hosted on Acast. See acast.com/privacy for more information.